Ginkgo Bioworks Holdings (DNA) financial statements
Ginkgo Bioworks Holdings reported revenue of $170M in fiscal 2025, up 21.0% a year over 6 years.
Net income was -$313M and the operating margin -185.3%, against -132.1% in 2019.
Free cash flow was -$179M.
The diluted share count rose 93% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Ginkgo Bioworks Holdings's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $54M | $77M | $314M | $478M | $251M | $227M | $170M |
| Research and development | $96M | $160M | $1.1B | $1.1B | $581M | $424M | $244M |
| Selling, general and admin | $29M | $38M | $863M | $1.4B | $385M | $246M | $183M |
| Operating income | -$72M | -$137M | -$1.8B | -$2.2B | -$864M | -$560M | -$315M |
| Interest expense | $2M | $2M | $2M | $106,000 | $93,000 | $94,000 | $0 |
| Pre-tax income | -$120M | -$125M | -$1.8B | -$2.1B | -$893M | -$548M | -$314M |
| Income tax | $22,000 | $2M | -$1M | -$15M | -$71,000 | -$479,000 | -$837,000 |
| Net income | -$119M | -$127M | -$1.8B | -$2.1B | -$893M | -$547M | -$313M |
| EPS (diluted) | -$4.00 | -$4.00 | -$55.60 | -$50.20 | -$18.37 | -$10.54 | -$5.64 |
| Diluted shares | 29M | 32M | 34M | 42M | 49M | 52M | 55M |
| Operating margin | -132.1% | -178.8% | -582.6% | -462.4% | -343.8% | -246.5% | -185.3% |
| Net margin | -220.2% | -165.2% | -583.1% | -440.6% | -355.1% | -240.9% | -183.8% |
Balance sheet
Fiscal years, from Ginkgo Bioworks Holdings's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $495M | $381M | $1.6B | $1.3B | $944M | $562M | $423M |
| Receivables | — | $17M | $132M | $81M | $17M | $22M | $24M |
| Inventory | — | $3M | $3M | $4M | $46,000 | — | — |
| Total current assets | — | $427M | $1.7B | $1.5B | $1.0B | $603M | $472M |
| Property, plant and equipment | — | $121M | $146M | $315M | $188M | $204M | $167M |
| Goodwill | $2M | $2M | $21M | $60M | $49M | $0 | — |
| Total assets | — | $675M | $2.1B | $2.5B | $1.7B | $1.4B | $1.1B |
| Total current liabilities | — | $73M | $135M | $173M | $164M | $107M | $96M |
| Total liabilities | — | $205M | $504M | $803M | $568M | $661M | $611M |
| Shareholders' equity | $502M | $461M | $1.5B | $1.7B | $1.1B | $716M | $509M |
| Net debt | -$495M | -$381M | -$1.6B | -$1.3B | -$944M | -$562M | -$167M |
Cash flow
Fiscal years, from Ginkgo Bioworks Holdings's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$45M | -$136M | -$254M | -$252M | -$296M | -$320M | -$171M |
| Capital spending | $22M | $58M | $57M | $52M | $41M | $63M | $8M |
| Free cash flow | -$67M | -$194M | -$310M | -$304M | -$336M | -$382M | -$179M |
| Stock-based compensation | $771,000 | $476,000 | $1.6B | $1.9B | $230M | $112M | $82M |
| Share buybacks (net) | -$408,000 | — | — | — | — | — | — |
| Free cash flow margin | -123.4% | -252.6% | -98.9% | -63.7% | -133.7% | -168.3% | -105.0% |
Questions
What was Ginkgo Bioworks Holdings's revenue in 2025?
$170M in fiscal 2025, from its 10-K filing.
How much free cash flow does Ginkgo Bioworks Holdings generate?
-$179M in fiscal 2025 (operating cash flow minus capital spending).
From Ginkgo Bioworks Holdings's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.